Evidence map›Paper›PMID 28414303›Full record

ArticleGene therapy2017

Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo.

M L Palma, P Duangkhae, B Douradinha, I F T Viana, P O Rigato, R Dhalia, R B Mailliard, S M Barratt-Boyes, E J M Nascimento, T M Oshiro and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

M L PalmaUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.ORCID 0000-0002-9194-6680
P DuangkhaeUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.
B DouradinhaUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.
I F T VianaUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.ORCID 0000-0003-4648-6635
P O RigatoLaboratory of Dermatology and Immunodeficiencies, School of Medicine from University of São Paulo, São Paulo, Brazil.
R DhaliaVirology and Experimental Virology Department, Aggeu Magalhães Research Center, Fiocruz, Recife, Brazil.
R B MailliardDepartment of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA.
S M Barratt-BoyesUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.
E J M NascimentoUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.
T M OshiroLaboratory of Dermatology and Immunodeficiencies, School of Medicine from University of São Paulo, São Paulo, Brazil.
A J da Silva DuarteLaboratory of Dermatology and Immunodeficiencies, School of Medicine from University of São Paulo, São Paulo, Brazil.
E T A MarquesUniversity of Pittsburgh Center for Vaccine Research, Pittsburgh, PA, USA.
University of Pittsburgh · USUniversidade de São Paulo · BRFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Class II transactivator (CIITA) induces transcription of major histocompatibility complex (MHC) II genes and can potentially be used to improve genetic immunotherapies by converting non-immune cells into cells capable of presenting antigens to CD4

Indexed as

Genes, MHC Class IIGene Transfer TechniquesGenetic TherapyGenetic VectorsHEK293 CellsHeLa CellsHumansLentivirusSkinTrans-ActivatorsTrans-Activators

Identifiers

PMID28414303
OpenAlexW2606897022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.